Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Healthcare Times Denmark.
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
Press Release – No. 3 / 2025 Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results Copenhagen, Denmark, February 13, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a...
IO Biotech to Present at the 45th Annual Cowen Health Care Conference
Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted) NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical...
Newsweek and Statista Unveil the World’s Best Hospitals 2025 Rankings, Featuring Expanded Quality Metrics and Patient-Reported Outcomes
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Newsweek, the modern global digital news organization, in partnership with Statista, has released its official World’s Best Hospitals 2025 rankings, recognizing top-performing hospitals across 30...
Archeon Medical and Ambu announce their collaboration for distribution of EOlife and EOlifeX
NEW-YORK, NY, UNITED STATES, February 20, 2025 /EINPresswire.com/ -- Archeon Medical, a pioneer in life-saving medical devices, and Ambu, a world-renowned leader in healthcare solutions, proudly announce a strategic partnership that promises to...
Rezilient Health's Hybrid Care Model Outperforms Traditional In-Person Healthcare
"The data conclusively shows that our hybrid care model exceeds the quality of in-person care," said Danish Nagda, MD, CEO and Co-Founder at Rezilient Health. ST. LOUIS, MO, UNITED STATES, February 11, 2025 /EINPresswire.com/ -- Rezilient...
Sex-Based Drug Development Market Trends, Competitive Analysis and Segmentations Report
Ottawa, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The global sex-based drug development market is rising because increasing awareness of gender-specific sexual health disorders, together with regulatory momentum, clinical innovations, and growing demand...
Top Growth Driver in the Odactra Market 2025: Rising Prevalence Of Allergic Diseases Propels Growth
The Business Research Company's Top Growth Driver in the Odactra Market 2025: Rising Prevalence Of Allergic Diseases Propels Growth LONDON, GREATER LONDON, UNITED KINGDOM, February 7, 2025 /EINPresswire.com/ -- Updated 2025 Market Reports...
Menstrual Cup Market to Reach USD 2.5B by 2032, Eco-Friendly Reusable Cups, Smart Designs & Sustainable Hygiene Trends
The global menstrual cup market is expanding rapidly, due to growing environmental awareness and cost-effectiveness. WILMINGTON, DE, UNITED STATES, October 20, 2025 /EINPresswire.com/ -- Explore the booming Menstrual Cup Market, valued at USD...
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
– Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares COPENHAGEN, Denmark, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced...
Compounding Pharmacy Market Size Expected to Reach USD 22.91 Bn by 2034
Ottawa, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The global compounding pharmacy market size was valued at USD 13.86 billion in 2024 and is predicted to hit around USD 21.79 billion by 2033, a study published by Towards Healthcare a sister firm of...
ISS signs new contract with financial services company in Türkiye
Copenhagen, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Under the new contract, ISS will deliver integrated facility services, including cleaning, technical maintenance, and other support services. The contract starts on 1 November 2025 and has a one-year...
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025
COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the U.S....
Generative AI in the Drug Discovery Market Size to Attain USD 2847.43 Million, Rising at 27.42% CAGR by 2034
Ottawa, Oct. 10, 2025 (GLOBE NEWSWIRE) -- The global generative AI in drug discovery market size was valued at USD 250 million in 2024 and is predicted to hit around USD 2847.43 million by 2034, rising at a 27.42% CAGR, a study published by...
Viral Vector Gene Therapy Market Size Expects to Reach USD 38.39 Billion by 2034
Ottawa, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The global viral vector gene therapy market size was valued at USD 13.14 billion in 2024 and is predicted to hit around USD 38.39 billion by 2034, rising at a 11.23% CAGR, a study published by Towards...
Alternative Medicines and Therapies Market Forecast to Grow at 6.66% CAGR, Hitting 202.3 Billion USD by 2032 | Herbalife
The Global Alternative Medicines and Therapies Market is experiencing significant growth, driven by increasing consumer awareness NEW YORK , NY, UNITED STATES, January 16, 2025 /EINPresswire.com/ -- 𝚆𝙶𝚁 released the report titled "Alternative...
Beef Market to Reach USD 650.9 Billion by 2032, Driven by Growing Health Consciousness
Beef Market Research Report Information By Cut Type, By Distribution Channel, and By Region NEW YORK, NY, UNITED STATES, February 21, 2025 /EINPresswire.com/ -- Beef Industry is poised for steady growth, driven by increasing consumer demand,...
Epitopea Appoints Klaus Edvardsen M.D., Ph.D. as Chief Medical Officer
CAMBRIDGE, United Kingdom and MONTREAL, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, announces the appointment of Dr. Klaus Edvardsen...
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
– Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million – Following pre-NDA meeting with FDA, on track to submit TransCon™ CNP NDA for achondroplasia in children in Q1...
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a...